Trade

with

Aegerion Pharmaceuticals Inc
(NASDAQ: AEGR)
AdChoices
31.59
+0.57
+1.84%
After Hours :
-
-
-

Open

31.09

Previous Close

31.02

Volume (Avg)

241.20k (1.10M)

Day's Range

30.81-31.99

52Wk Range

26.25-101.00

Market Cap.

916.26M

Dividend Rate ( Yield )

-

Beta

-0.22

Shares Outstanding

29.55M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 48.55M

    • Net Income

    • -63.36M

    • Market Cap.

    • 916.26M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -49.82

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -0.22

    • Forward P/E

    • 16.95

    • Price/Sales

    • 8.76

    • Price/Book Value

    • 8.60

    • Price/Cash flow

    • -36.76

      • EBITDA

      • -61.82M

      • Return on Capital %

      • -38.05

      • Return on Equity %

      • -46.28

      • Return on Assets %

      • -38.05

      • Book Value/Share

      • 3.61

      • Shares Outstanding

      • 29.55M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 58.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 1.83

        • Cashflow Estimate

        • 2.98

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 454.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 89.47

            • 82.75

            • Pre-Tax Margin

            • -49.17

            • 39.38

            • Net Profit Margin

            • -49.82

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.02

              • 0.76

              • Current Ratio

              • 5.45

              • 2.92

              • Quick Ratio

              • 4.87

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.26

              • 2.21

              • Book Value/Share

              • 3.61

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -17.61

                • 188.68

                • P/E Ratio 5-Year High

                • -57.25

                • 634.30

                • P/E Ratio 5-Year Low

                • -5.10

                • 124.82

                • Price/Sales Ratio

                • 8.77

                • 8.72

                • Price/Book Value

                • 8.61

                • 7.95

                • Price/Cash Flow Ratio

                • -36.76

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -46.28

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -38.05

                    (-106.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -43.33

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 2.64

                  • 1.48

                  • Asset Turnover

                  • 0.76

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -62.35M
                  Operating Margin
                  -128.43
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -36.76
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  90.89%

                  Mutual Fund Ownership

                  57.81%

                  Float

                  63.66%

                  5% / Insider Ownership

                  1.65%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,572,385

                  • 13.32

                  • 8.71

                  • Putnam Voyager Fund

                  •  

                    1,094,200

                  • 107.59

                  • 3.71

                  • Lord Abbett Fundamental Equity

                  •  

                    1,079,045

                  • 37.56

                  • 3.65

                  • Putnam Equity Spectrum Fund

                  •  

                    1,033,900

                  • 4.52

                  • 3.50

                  • Fidelity® Independence Fund

                  •  

                    735,000

                  • 0.00

                  • 2.49

                  • JPMorgan Growth Advantage Fund

                  •  

                    574,990

                  • 0.00

                  • 1.95

                  • SPDR® S&P Biotech ETF

                  •  

                    526,532

                  • 0.60

                  • 1.66

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    492,567

                  • 12.94

                  • 1.67

                  • Vanguard Small Cap Index

                  •  

                    462,151

                  • -0.10

                  • 1.56

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Scopia Management Inc.

                  •  

                    5,175,201

                  • +23.65%

                  • 17.52

                  • Fidelity Management and Research Company

                  •  

                    3,751,574

                  • -14.52%

                  • 12.71

                  • Putnam Investment Management,LLC

                  •  

                    3,452,096

                  • +81.15%

                  • 11.69

                  • Westfield Capital Management Company, LP

                  •  

                    3,207,598

                  • +86.88%

                  • 10.86

                  • Lord, Abbett & Co LLC

                  •  

                    2,100,782

                  • +34.34%

                  • 7.12

                  • Vanguard Group, Inc.

                  •  

                    1,622,706

                  • +1.80%

                  • 5.50

                  • J.P. Morgan Investment Management Inc.

                  •  

                    1,233,307

                  • -16.57%

                  • 4.18

                  • BlackRock Fund Advisors

                  •  

                    1,233,068

                  • +9.87%

                  • 4.18

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company curr...moreently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules (“JUXTAPID”). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein (“LDL”) apheresis where available, to reduce low-density lipoprotein cholesterol (“LDL-C”), total cholesterol (“TC”), apolipoprotein B (“apo B”) and non-high-density lipoprotein cholesterol (“non-HDL-C”) in adult patients with homozyg...moreous familial hypercholesterolemia (“HoFH”). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company’s operations are subject to federal, state and local level, the EU and other countries extensively regulations.lessless

                  Key People

                  Mr. Marc D. Beer

                  CEO/Director

                  Mr. David I. Scheer

                  Chairman of the Board/Director/Co-Founder

                  Mr. Mark J. Fitzpatrick

                  CFO/Chief Accounting Officer

                  Johanna Sealscott

                  Vice President, Divisional

                  Dr. Antonio M. Gotto,Jr,M.D.,D.Phil.

                  Director

                  • Aegerion Pharmaceuticals Inc

                  • 101 Main Street, Suite 1850

                  • Cambridge, MA 02142

                  • USA.Map

                  • Phone: +1 617 500-7867

                  • Fax: +1 617 945-7968

                  • aegerion.com

                  Incorporated

                  2005

                  Employees

                  256

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: